This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB04875/identifier/chemspider/
n6http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB04875/identifier/bindingdb/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04875/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB04875/identifier/pubchem-substance/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04875/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB04875
rdf:type
n3:Drug
n3:description
Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).
n3:generalReferences
# Ross J, Brough D, Gibson RM, Loddick SA, Rothwell NJ: A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat. Neuropharmacology. 2007 Oct;53(5):638-42. Epub 2007 Aug 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17845807 # Loher F, Bauer C, Landauer N, Schmall K, Siegmund B, Lehr HA, Dauer M, Schoenharting M, Endres S, Eigler A: The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J Pharmacol Exp Ther. 2004 Feb;308(2):583-90. Epub 2003 Nov 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14610233 # Rudolphi K, Gerwin N, Verzijl N, van der Kraan P, van den Berg W: Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage. 2003 Oct;11(10):738-46. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/13129693
n3:group
investigational
n3:indication
For the treatment of rheumatoid arthritis (RA).
owl:sameAs
n6:DB04875
dcterms:title
Pralnacasan
adms:identifier
n8:10251744 n9:DB04875 n10:153270 n11:50189360 n12:135089
n3:mechanismOfAction
Pralnacasan inhibits interleukin-1beta converting enzyme (ICE), an enzyme that regulates the production of IL-1 and IFN gamma - intercellular mediators that initiate and sustain the process of inflammation. Inhibiting ICE may be an effective strategy for curtailing damaging inflammatory processes common to a number of acute and chronic conditions, such as rheumatoid arthritis (RA) and osteoarthritis.
n3:synonym
HMR 3480
n3:IUPAC-Name
n4:271B5BF3-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5BF9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5BF8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5BF5-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5BF6-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5BF7-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5BF1-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5BEF-363D-11E5-9242-09173F13E4C5 n4:271B5BF2-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5BF0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5BFF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5C00-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5BFA-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5BFB-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5BFD-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5BFC-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5BFE-363D-11E5-9242-09173F13E4C5
n3:absorption
Orally bioavailable
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
192755-52-5
n3:Bioavailability
n4:271B5C05-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5C07-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5C08-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5C04-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5C03-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5C06-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5BF4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5C01-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5C02-363D-11E5-9242-09173F13E4C5